{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:33Z","timestamp":1772119473753,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"crossref","award":["2024NSFSC1880"],"award-info":[{"award-number":["2024NSFSC1880"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82302993"],"award-info":[{"award-number":["82302993"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01912-8","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:55:34Z","timestamp":1762844134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Platelet CKB as a potential contributor to serum creatine kinase abnormalities and metastasis in cancer patients"],"prefix":"10.1007","volume":"25","author":[{"given":"Lubei","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanbin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"1912_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2024-004422","author":"J Walters","year":"2025","unstructured":"Walters J, Gailani G. Serum creatine kinase: requesting and interpreting results. Pract Neurol. 2025. https:\/\/doi.org\/10.1136\/pn-2024-004422.","journal-title":"Pract Neurol"},{"issue":"2","key":"1912_CR2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2012.03.012","volume":"57","author":"Y Soroida","year":"2012","unstructured":"Soroida Y, Ohkawa R, Nakagawa H, Satoh Y, Yoshida H, Kinoshita H, et al. Increased activity of serum mitochondrial isoenzyme of creatine kinase in hepatocellular carcinoma patients predominantly with recurrence. J Hepatol. 2012;57(2):330\u20136.","journal-title":"J Hepatol"},{"key":"1912_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/978-981-10-7757-9_13","volume":"87","author":"U Schlattner","year":"2018","unstructured":"Schlattner U, Kay L, Tokarska-Schlattner M. Mitochondrial proteolipid complexes of creatine kinase. Subcell Biochem. 2018;87:365\u2013408.","journal-title":"Subcell Biochem"},{"issue":"1","key":"1912_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(94)90248-8","volume":"231","author":"F Kanemitsu","year":"1994","unstructured":"Kanemitsu F, Okigaki T. Characterization of human creatine kinase BB and MB isoforms by means of isoelectric focusing. Clin Chim Acta. 1994;231(1):1\u20139.","journal-title":"Clin Chim Acta"},{"issue":"2","key":"1912_CR5","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1515\/cclm-2020-0811","volume":"59","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han F, Liu X, Xie C, Tian K, Bi Q, et al. Macro creatine kinase in an asymptomatic patient: a case report. Clin Chem Lab Med. 2020;59(2):e61\u20134.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1912_CR6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bbadis.2005.09.004","volume":"1762","author":"U Schlattner","year":"2006","unstructured":"Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta. 2006;1762(2):164\u201380.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1912_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/clinchem\/hvab066","volume":"67","author":"P Collinson","year":"2021","unstructured":"Collinson P, Suvisaari J, Aakre KM, Baum H, Duff CJ, Gruson D, et al. How well do laboratories adhere to recommended guidelines for cardiac biomarkers management in Europe? The CArdiac MARker guideline uptake in Europe (CAMARGUE) study of the european federation of laboratory medicine task group on cardiac markers. Clin Chem. 2021;67(8):1144\u201352.","journal-title":"Clin Chem"},{"issue":"10","key":"1912_CR8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1001\/jamainternmed.2017.3597","volume":"177","author":"MD Alvin","year":"2017","unstructured":"Alvin MD, Jaffe AS, Ziegelstein RC, Trost JC. Eliminating creatine kinase-myocardial band testing in suspected acute coronary syndrome: a value-based quality improvement. JAMA Intern Med. 2017;177(10):1508\u201312.","journal-title":"JAMA Intern Med"},{"key":"1912_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143353","author":"A Grela-Wojewoda","year":"2022","unstructured":"Grela-Wojewoda A, P\u00fcsk\u00fcll\u00fco\u011flu M, Sas-Korczy\u0144ska B, Zeme\u0142ka T, Pacholczak-Madej R, Wysocki WM, et al. Biomarkers of trastuzumab-induced cardiac toxicity in HER2- positive breast cancer patient population. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14143353.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1912_CR10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0009-8981(92)90088-8","volume":"206","author":"F Kanemitsu","year":"1992","unstructured":"Kanemitsu F, Okigaki T. Creatine kinase MB isoforms for early diagnosis and monitoring of acute myocardial infarction. Clin Chim Acta. 1992;206(3):191\u20139.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1912_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(86)90093-8","volume":"155","author":"M Panteghini","year":"1986","unstructured":"Panteghini M, Cuccia C, Malchiodi A, Calarco M, Pagnoni N. Isoforms of creatine kinase MM and MB in acute myocardial infarction: a clinical evaluation. Clin Chim Acta. 1986;155(1):1\u20139.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1912_CR12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0009-8981(76)90146-7","volume":"73","author":"D Neumeier","year":"1976","unstructured":"Neumeier D, Prellwitz W, W\u00fcrzburg U, Brundobler M, Olbermann M, Just HJ, et al. Determination of creatine kinase isoenzyme MB activity in serum using immunological inhibition of creatine kinase M subunit activity. Activity kinetics and diagnostic significance in myocardial infarction. Clin Chim Acta. 1976;73(3):445\u201351.","journal-title":"Clin Chim Acta"},{"issue":"7\u20138","key":"1912_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00508-012-0155-8","volume":"124","author":"FM Kovar","year":"2012","unstructured":"Kovar FM, Aldrian S, Endler G, V\u00e9csei V, Hajdu S, Heinz T, et al. CK\/CK-MB ratio as an indirect predictor for survival in polytraumatized patients. Wien Klin Wochenschr. 2012;124(7\u20138):245\u201350.","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"1912_CR14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000505724","volume":"13","author":"T Ota","year":"2020","unstructured":"Ota T, Hasegawa Y, Murata E, Tanaka N, Fukuoka M. False-positive elevation of CK-MB levels with chest pain in lung adenocarcinoma. Case Rep Oncol. 2020;13(1):100\u20134.","journal-title":"Case Rep Oncol"},{"issue":"3","key":"1912_CR15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1515\/dx-2018-0039","volume":"6","author":"A Eidizadeh","year":"2019","unstructured":"Eidizadeh A, von Ahsen N, Friedewald S, Binder L. Macro-CK type 2 in metastatic prostate cancer. Diagnosis (Berl). 2019;6(3):307\u20139.","journal-title":"Diagnosis (Berl)"},{"issue":"2","key":"1912_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/ajcp\/79.2.255","volume":"79","author":"TM Annesley","year":"1983","unstructured":"Annesley TM, McKenna BJ. Ectopic creatine kinase MB production in metastatic cancer. Am J Clin Pathol. 1983;79(2):255\u20139.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"1912_CR17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cell.2014.12.018","volume":"160","author":"JM Loo","year":"2015","unstructured":"Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, et al. Extracellular metabolic energetics can promote cancer progression. Cell. 2015;160(3):393\u2013406.","journal-title":"Cell"},{"issue":"4","key":"1912_CR18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.str.2025.01.008","volume":"33","author":"M Demir","year":"2025","unstructured":"Demir M, Koepping L, Li Y, Fujimoto L, Bobkov A, Zhao J, et al. Structural basis for substrate binding, catalysis, and inhibition of cancer target mitochondrial creatine kinase by a covalent inhibitor. Structure. 2025;33(4):786-797.e783.","journal-title":"Structure"},{"issue":"15","key":"1912_CR19","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.7314\/APJCP.2015.16.15.6599","volume":"16","author":"CC Chang","year":"2015","unstructured":"Chang CC, Liou CB, Su MJ, Lee YC, Liang CT, Ho JL, et al. Creatine kinase (CK)-MB-to-total-CK ratio: a laboratory indicator for primary cancer screening. Asian Pac J Cancer Prev. 2015;16(15):6599\u2013603.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"9","key":"1912_CR20","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/ijc.28547","volume":"134","author":"B Uranbileg","year":"2014","unstructured":"Uranbileg B, Enooku K, Soroida Y, Ohkawa R, Kudo Y, Nakagawa H, et al. High ubiquitous mitochondrial creatine kinase expression in hepatocellular carcinoma denotes a poor prognosis with highly malignant potential. Int J Cancer. 2014;134(9):2189\u201398.","journal-title":"Int J Cancer"},{"issue":"1","key":"1912_CR21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbrc.2012.08.147","volume":"427","author":"XL Qian","year":"2012","unstructured":"Qian XL, Li YQ, Gu F, Liu FF, Li WD, Zhang XM, et al. Overexpression of ubiquitous mitochondrial creatine kinase (uMtCK) accelerates tumor growth by inhibiting apoptosis of breast cancer cells and is associated with a poor prognosis in breast cancer patients. Biochem Biophys Res Commun. 2012;427(1):60\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1912_CR22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/JCMA.0000000000000259","volume":"83","author":"YC Lin","year":"2020","unstructured":"Lin YC, Chen SC, Huang CM, Hu YF, Chen YY, Chang SL, et al. Clinical features and diagnosis of new malignancy in patients with acute pulmonary embolism and without a history of cancer. J Chin Med Assoc. 2020;83(3):245\u201350.","journal-title":"J Chin Med Assoc"},{"issue":"7","key":"1912_CR23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/clinchem\/31.7.1189","volume":"31","author":"W Stein","year":"1985","unstructured":"Stein W, Bohner J. Influence of autoantibodies to creatine kinase-BB on assays for MB isoenzyme. Clin Chem. 1985;31(7):1189\u201392.","journal-title":"Clin Chem"},{"issue":"6","key":"1912_CR24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/clinchem\/33.6.809","volume":"33","author":"SS Wong","year":"1987","unstructured":"Wong SS, Wu AH, Fritsche HA. Reassessment of creatine kinase BB as a marker for cancer of the prostate, breast, and lung. Clin Chem. 1987;33(6):809\u201311.","journal-title":"Clin Chem"},{"issue":"1","key":"1912_CR25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2004.08.047","volume":"96","author":"HG Huddleston","year":"2005","unstructured":"Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol. 2005;96(1):77\u201383.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1912_CR26","first-page":"270","volume":"55","author":"HC Wang","year":"1995","unstructured":"Wang HC, Lu JY, Ting YM. Elevated serum CK-MB and CK-BB isoenzymes in a patient with small cell lung cancer: a case report. Zhonghua Yi Xue Za Zhi (Taipei). 1995;55(3):270\u20133.","journal-title":"Zhonghua Yi Xue Za Zhi (Taipei)"},{"key":"1912_CR27","volume":"37","author":"Y Li","year":"2023","unstructured":"Li Y, Chen Y, Shao B, Liu J, Hu R, Zhao F, et al. Evaluation of creatine kinase (CK)-MB to total CK ratio as a diagnostic biomarker for primary tumors and metastasis screening. Pract Lab Med. 2023;37:e00336.","journal-title":"Pract Lab Med"},{"issue":"11","key":"1912_CR28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2169\/internalmedicine.56.8329","volume":"56","author":"Y Wada","year":"2017","unstructured":"Wada Y, Tanigawa J, Ishizaka N. Macro-CK and CK-BB contributing to sham CK-MB elevation. Intern Med. 2017;56(11):1449\u201350.","journal-title":"Intern Med"},{"issue":"7 Pt 1","key":"1912_CR29","first-page":"1278","volume":"40","author":"KN Lee","year":"1994","unstructured":"Lee KN, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem. 1994;40(7 Pt 1):1278\u201383.","journal-title":"Clin Chem"},{"issue":"12","key":"1912_CR30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/2159-8290.CD-12-0329","volume":"2","author":"M Labelle","year":"2012","unstructured":"Labelle M, Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov. 2012;2(12):1091\u20139.","journal-title":"Cancer Discov"},{"issue":"4","key":"1912_CR31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.12381","volume":"162","author":"AM Gil-Bernab\u00e9","year":"2013","unstructured":"Gil-Bernab\u00e9 AM, Lucotti S, Muschel RJ. Coagulation and metastasis: what does the experimental literature tell us? Br J Haematol. 2013;162(4):433\u201341.","journal-title":"Br J Haematol"},{"issue":"18","key":"1912_CR32","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1158\/0008-5472.CAN-11-4010","volume":"72","author":"LA Coupland","year":"2012","unstructured":"Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res. 2012;72(18):4662\u201371.","journal-title":"Cancer Res"},{"issue":"1","key":"1912_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","volume":"11","author":"M Schlesinger","year":"2018","unstructured":"Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11(1):125.","journal-title":"J Hematol Oncol"},{"issue":"17","key":"1912_CR34","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1182\/blood-2009-10-247296","volume":"115","author":"L Erpenbeck","year":"2010","unstructured":"Erpenbeck L, Sch\u00f6n MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115(17):3427\u201336.","journal-title":"Blood"},{"issue":"1","key":"1912_CR35","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jth.15543","volume":"20","author":"N Martins Castanheira","year":"2022","unstructured":"Martins Castanheira N, Spanhofer AK, Wiener S, Bobe S, Schillers H. Uptake of platelets by cancer cells and recycling of the platelet protein CD42a. J Thromb Haemost. 2022;20(1):170\u201381.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1912_CR36","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","volume":"72","author":"T Placke","year":"2012","unstructured":"Placke T, \u00d6rgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"1912_CR37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.1103194","volume":"189","author":"T Placke","year":"2012","unstructured":"Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol. 2012;189(1):154\u201360.","journal-title":"J Immunol"},{"key":"1912_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030277","author":"KL Clar","year":"2019","unstructured":"Clar KL, Hinterleitner C, Schneider P, Salih HR, Maurer S. Inhibition of NK reactivity against solid tumors by platelet-derived RANKL. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11030277.","journal-title":"Cancers (Basel)"},{"key":"1912_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040855","author":"D Stoiber","year":"2020","unstructured":"Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020. https:\/\/doi.org\/10.3390\/cells9040855.","journal-title":"Cells"},{"issue":"1","key":"1912_CR40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12885-024-12307-5","volume":"24","author":"L Rao","year":"2024","unstructured":"Rao L, Xu P, Zhang G, Zu R, Luo Y, Zhang K, et al. Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection. BMC Cancer. 2024;24(1):543.","journal-title":"BMC Cancer"},{"issue":"1","key":"1912_CR41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0009-8981(87)90106-9","volume":"164","author":"A Usui","year":"1987","unstructured":"Usui A, Fujita K, Imaizumi M, Abe T, Inoue K, Matumoto S, et al. Determination of creatine kinase isozymes in sera and tissues of patients with various lung carcinomas. Clin Chim Acta. 1987;164(1):47\u201353.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"1912_CR42","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cmet.2018.11.009","volume":"28","author":"I Ben-Sahra","year":"2018","unstructured":"Ben-Sahra I, Puissant A. HER2 signaling hijacks the creatine shuttle to fuel breast cancer cell growth. Cell Metab. 2018;28(6):805\u20137.","journal-title":"Cell Metab"},{"key":"1912_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010027","author":"RI Krutilina","year":"2021","unstructured":"Krutilina RI, Playa H, Brooks DL, Schwab LP, Parke DN, Oluwalana D, et al. HIF-dependent CKB expression promotes breast cancer metastasis, whereas cyclocreatine therapy impairs cellular invasion and improves chemotherapy efficacy. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers14010027.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1912_CR44","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/bjc.1996.66","volume":"73","author":"N Zarghami","year":"1996","unstructured":"Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, et al. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. Br J Cancer. 1996;73(3):386\u201390.","journal-title":"Br J Cancer"},{"key":"1912_CR45","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/clinchem\/40.7.1278","volume":"40","author":"K Lee","year":"1994","unstructured":"Lee K, Csako G, Bernhardt P, Elin RJ. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem. 1994;40:1278\u201383.","journal-title":"Clin Chem"},{"issue":"3","key":"1912_CR46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2478\/s11658-009-0014-4","volume":"14","author":"S Bera","year":"2009","unstructured":"Bera S, Ray M. The transcriptional cascade associated with creatine kinase down-regulation and mitochondrial biogenesis in mice sarcoma. Cell Mol Biol Lett. 2009;14(3):481\u201396.","journal-title":"Cell Mol Biol Lett"},{"key":"1912_CR47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fphar.2019.00741","volume":"10","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Sun M, Chen Y, Li B. Mir-519b-3p inhibits the proliferation and invasion in colorectal cancer via modulating the uMtCK\/Wnt signaling pathway. Front Pharmacol. 2019;10:741.","journal-title":"Front Pharmacol"},{"issue":"13","key":"1912_CR48","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1093\/clinchem\/26.13.1908","volume":"26","author":"JW Heinz","year":"1980","unstructured":"Heinz JW, O\u2019Donnell NJ, Lott JA. Apparent mitochondrial creatine kinase in the serum of a patient with metastatic cancer to the liver. Clin Chem. 1980;26(13):1908\u201311.","journal-title":"Clin Chem"},{"issue":"1","key":"1912_CR49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41419-025-07504-4","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wu H, Chang X, Song Y, Chen Y, Yan Z, et al. Ckmt1 deficiency contributes to mitochondrial dysfunction and promotes intestinal epithelial cell apoptosis via reverse electron transfer-derived ROS in colitis. Cell Death Dis. 2025;16(1):177.","journal-title":"Cell Death Dis"},{"key":"1912_CR50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.18632\/oncotarget.28436","volume":"14","author":"M Kita","year":"2023","unstructured":"Kita M, Fujiwara-Tani R, Kishi S, Mori S, Ohmori H, Nakashima C, et al. Role of creatine shuttle in colorectal cancer cells. Oncotarget. 2023;14:485\u2013501.","journal-title":"Oncotarget"},{"issue":"11","key":"1912_CR51","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70053","volume":"17","author":"H Zhang","year":"2024","unstructured":"Zhang H, To KKW. Serum creatine kinase elevation following tyrosine kinase inhibitor treatment in cancer patients: symptoms, mechanism, and clinical management. Clin Transl Sci. 2024;17(11):e70053.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1912_CR52","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/bjc.1997.432","volume":"76","author":"J Joseph","year":"1997","unstructured":"Joseph J, Cardesa A, Carreras J. Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer. 1997;76(5):600\u20135.","journal-title":"Br J Cancer"},{"key":"1912_CR53","doi-asserted-by":"crossref","unstructured":"Li M, Liu H, Li J, Guo S, Lv YJRr: Mitochondrial creatine kinase 1 in non-small cell lung cancer progression and hypoxia adaptation. 2021;22(1):190.","DOI":"10.1186\/s12931-021-01765-1"},{"key":"1912_CR54","volume":"12","author":"S Cai","year":"2024","unstructured":"Cai S, Xia Q, Duan D, Fu J, Wu Z, Yang Z, et al. Creatine kinase mitochondrial 2 promotes the growth and progression of colorectal cancer via enhancing Warburg effect through lactate dehydrogenase B. PeerJ. 2024;12:e17672.","journal-title":"PeerJ"},{"issue":"1","key":"1912_CR55","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/jca.13207","volume":"7","author":"R Amamoto","year":"2016","unstructured":"Amamoto R, Uchiumi T, Yagi M, Monji K, Song Y, Oda Y, et al. The expression of ubiquitous mitochondrial creatine kinase is downregulated as prostate cancer progression. J Cancer. 2016;7(1):50\u20139.","journal-title":"J Cancer"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01912-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01912-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:43Z","timestamp":1764917503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01912-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01912-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7113855\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"13 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The research related to human use has complied with all the relevant national regulations, institutional policies and follows the tenets of the Helsinki Declaration, and has been approved by the Institutional Ethics Committee of The Sichuan Cancer Hospital (IRB No. SCCHEC-02\u20132022-017).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The study was exempted from informed consent (IRB No. SCCHEC-02\u20132022-017).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"369"}}